{"id":"non-influenza-comparator-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Systemic reactions (fever, fatigue, myalgia)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Comparator vaccines in clinical trials are used as control arms to evaluate the efficacy and safety of investigational vaccines. This non-influenza comparator vaccine likely contains inactivated viral antigens, recombinant proteins, or other immunogenic components designed to elicit both humoral and cell-mediated immune responses. The specific mechanism depends on the vaccine platform and target antigen, but generally works by presenting foreign antigens to the immune system to generate memory B and T cells.","oneSentence":"A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:17.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 3 comparator vaccine (specific indication unknown without trial protocol details)"}]},"trialDetails":[{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT04806529","phase":"PHASE2, PHASE3","title":"An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older","status":"WITHDRAWN","sponsor":"Seqirus","startDate":"2020-12-15","conditions":"Influenza","enrollment":""},{"nctId":"NCT03165617","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-05-25","conditions":"Influenza, Human","enrollment":4514},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT02914275","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-27","conditions":"Influenza, Human","enrollment":2250},{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT02242643","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":2432},{"nctId":"NCT00764790","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Influenza","enrollment":3317},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT01346592","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Influenza Disease","enrollment":6104},{"nctId":"NCT01419925","phase":"PHASE2","title":"A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2011-08","conditions":"Influenza, Healthy","enrollment":120},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT00848887","phase":"PHASE1","title":"A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Influenza","enrollment":410},{"nctId":"NCT00975572","phase":"PHASE2","title":"Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2009-07","conditions":"Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":2200},{"nctId":"NCT01151059","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":138},{"nctId":"NCT01357265","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Influenza","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Non-influenza Comparator Vaccine","genericName":"Non-influenza Comparator Vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen. Used for Phase 3 comparator vaccine (specific indication unknown without trial protocol details).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}